Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Amicus Therapeutics (FOLD) over the last 16 years, with Q3 2025 value amounting to $1.6 million.

  • Amicus Therapeutics' Gains from Investment Securities fell 4122.49% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.7 million, marking a year-over-year decrease of 3545.82%. This contributed to the annual value of $22.0 million for FY2024, which is 2290.74% up from last year.
  • Per Amicus Therapeutics' latest filing, its Gains from Investment Securities stood at $1.6 million for Q3 2025, which was down 4122.49% from $432000.0 recorded in Q2 2025.
  • In the past 5 years, Amicus Therapeutics' Gains from Investment Securities registered a high of $16.7 million during Q1 2024, and its lowest value of $244000.0 during Q2 2021.
  • Moreover, its 5-year median value for Gains from Investment Securities was $1.7 million (2024), whereas its average is $4.5 million.
  • Examining YoY changes over the last 5 years, Amicus Therapeutics' Gains from Investment Securities showed a top increase of 77240.32% in 2021 and a maximum decrease of 9622.87% in 2021.
  • Quarter analysis of 5 years shows Amicus Therapeutics' Gains from Investment Securities stood at $5.3 million in 2021, then plummeted by 93.04% to $371000.0 in 2022, then surged by 321.83% to $1.6 million in 2023, then tumbled by 47.09% to $828000.0 in 2024, then soared by 98.19% to $1.6 million in 2025.
  • Its Gains from Investment Securities was $1.6 million in Q3 2025, compared to $432000.0 in Q2 2025 and $11.8 million in Q1 2025.